Munich, Germany, February 23, 2022 – SIRION Biotech GmbH is proud to announce our achievement of ISO 9001:2015 certification by DEKRA.
ISO 9001 is the worlds most widely recognized standard for a quality management system (QMS). It enables companies to operate more effectively on several different levels, including the ability to focus on customer requirements and constantly finding ways in which to improve and become resilient and sustainable. This ISO 9001:2015 certification reinforces SIRION’s ability to exceed the quality expectations and requirements of our customers.
“We are proud of our commitment to serving the scientific community, in particular cell and gene therapy developers, with the highest quality viral vectors” said Dieter Lingelbach, Chief Operations Officer at SIRION Biotech. “Customer satisfaction is at the center of everything we do and this ISO certification assures our customers that we continue to prioritize quality, reliability, and consistency in our manufacturing and management system processes today and in the future.”
In addition to ensuring that SIRION Biotech customers receive consistent, high-quality products and services, ISO 9001:2015 brings many business benefits. Our goals when embarking on certification were simple:
- Homogenous, repeatable, and secure internal process execution
- Creation of a platform for consistency during expansion
- Improved client delivery services and customer satisfaction
“We created a Quality Management Manual that recognizes the significant role our employees play in the quality of all SIRION Biotech services. This QMM, along with an existing quality assurance structure, provided the foundation for our ISO 9001:2015 Certification, and includes all aspects of Service Delivery, Business Enablement, Infrastructure, Human Resources and Training, Finance and Accounting, and Business Growth. It gives us a clear, actionable, and thorough approach to the vital components of our business and is positions us well for ongoing growth” said Katrin Becker, Head of Quality Assurance.
About SIRION Biotech
SIRION Biotech was founded in 2005 with the goal to spark a new generation of viral vector technologies for gene and cell therapy as well as vaccine development. SIRION evolves novel therapeutic viral vectors and uses proprietary technology platforms based on lenti-, adeno-, and adeno-associated viruses, to expedite its partners’ advances in drug development. On August 31, 2021, SIRION was taken over entirely by PerkinElmer. For additional information, please visit www.sirion-biotech.com.